Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics Corp has demonstrated a consistent growth trajectory in system utilization, experiencing an average increase of approximately 6.1% per quarter over the past six quarters. The company has committed to prudent financial management by curtailing the growth of operating expenses to half the rate of top-line growth, positioning itself for improved profitability. Additionally, management has expressed confidence in its product pipeline, anticipating a record number of system placements in the upcoming quarter, with recent placements surpassing previous guidance despite a challenging macroeconomic backdrop.

Bears say

PROCEPT BioRobotics Corp has seen a significant decline in share value, down approximately 54% year-to-date, despite its ability to exceed its own revenue guidance. The company faces multiple fundamental challenges, including a decrease in demand for capital equipment, reduced usage of handpieces by customers, intensified competition, and potential changes in reimbursement policies for its key therapy, Aquablation. These factors contribute to a negative outlook, as they are likely to dampen sales projections and investor sentiment moving forward.

PRCT has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 8 analysts, PRCT has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.